Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China

BACKGROUND: Infliximab was the first approved biologic treatment for moderate to severe Crohn’s disease (MS-CD) in China. However, the cost-effectiveness of infliximab maintenance therapy (IMT) for MS-CD relative to conventional maintenance therapy remained unclarified.  AIM: To assess the cost-effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Ji-Hao, Luo, Liang, Chen, Xiao-Li, Pan, Yi-Peng, Zhang, Zhou, Fang, Hao, Chen, Ying, Chen, Wen-Dong, Cao, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656205/
https://www.ncbi.nlm.nih.gov/pubmed/33244205
http://dx.doi.org/10.3748/wjg.v26.i41.6455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656205/
https://www.ncbi.nlm.nih.gov/pubmed/33244205
http://dx.doi.org/10.3748/wjg.v26.i41.6455

Ejemplares similares